CClinicalTrials.gg
CompletedNCT05787353Updated Mar 30, 2023

Cardiopulmonary Rehabilitation for Post-acute COVID-19 Symptoms

An interventional study of Exercise programme in Cardiopulmonary, sponsored by Eskisehir City Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-30.

Sponsored by Eskisehir City Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Apr 2021, registered Mar 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this RETROSPECTIVE study was to compare the effect of a hospital and home-based cardiopulmonary rehabilitation (CPR) program on exercise endurance and quality of life in post-acute COVID-19 patients.

88 post-acute COVID-19 patients were divided two groups according to receiving hospital (n=45) or home-based CPR (n=43)in our rehabilitation clinic between January and July 2021. Both protocols consisted of aerobic, breathing and flexibility exercises. Hospital-based CPR: three or four days per week for a total of 20 sessions. Home-based CPR: three or four days/a week over a period of six weeks. The results of six meters walk test (6MWT) for exercise endurance as a main outcome measure, and Borg-dyspnea/fatigue, the visual analog scale (VAS) for pain and the Short Form-36 (SF-36) as secondary outcome measures before and after treatment were recorded.

02

Conditions studied

  • Cardiopulmonary
03

In context

Lead sponsor

Eskisehir City Hospital is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • being 18 years or older
  • having COVID-19 treatment (home quarantine/hospital/intensive care unit) according to a positive polymerase chain reaction (PCR) test in a nasopharyngeal + oropharyngeal swab or chest computed tomography (CT)
  • participating in a home-based exercise program (for 6 weeks) or hospital-based CPR (for 12-20 sessions) due to post-acute COVID-19 symptoms (fatigue, myalgia, dyspnea).

Exclusion criteria

Exclusion Criteria:

  • Patients who had both a negative PCR test and chest CT
  • Patients who had not completed the six minute walk test (6MWT), Borg scales, Short Form-36 and Visual analog scale-pain.
  • Acute COVID-19 patients (patients whose symptoms had started less than one month previous)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Home based cardiopulmonary rehabilitation group

    This was a retrospective study. 43 patients who had home based cardiopulmonary rehabilitation programme between January and July 2023, in our rehabilitation clinic.

    Other: Exercise programme

  • Experimental
    Hospital based cardiopulmonary rehabilitation group

    This was a retrospective study. 45 patients who had hospital based cardiopulmonary rehabilitation programme between January and July 2023, in our rehabilitation clinic.

    Other: Exercise programme

Interventions

  • OtherExercise programme

    Both protocols consisted of aerobic, breathing and flexibility exercises. Hospital-based CPR: three or four days per week for a total of 20 sessions. Home-based CPR: three or four days/a week over a period of six weeks.

06

What researchers measure

Primary outcomes

  1. Exercise endurance

    Six minutes walk test (All patients walked along a 30-meter-long corridor without obstacles at their normal walking speed, how many meters they walked was noted.)

    Time frame: One day before exercise programme start and one day later exercise programme ends

Secondary outcomes

  1. Dyspnea

    Borg scale were also measured before and after 6MWT for perceived dyspnea (scale range from 0 to 10)

    Time frame: One day before exercise programme start and one day later exercise programme ends

  2. Muscle fatigue

    Borg muscle fatigue (scale range from 6 to 20: higher values show more severe symptoms)

    Time frame: One day before exercise programme start and one day later exercise programme ends

  3. short form 36

    A quality-of-life assessment was performed using the Short Form-36, which has 36 items regarding physical function, physical role, emotional role, energy, body pain, mental health, general health, and social function. The scale ranges from 0 (poor health) to 100 (perfect health)

    Time frame: One day before exercise programme start and one day later exercise programme ends

  4. Musculoskeletal Pain

    Visual analog scale-pain was used to measure general body musculoskeletal pain, which was assessed from 0 (no pain) to 10 (worst possible pain)

    Time frame: One day before exercise programme start and one day later exercise programme ends

07

Study locations

1 site
  • Eskişehir Osmangazi University
    Eskişehir, Odunpazarı, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05787353
Lead sponsor
Eskisehir City Hospital
Responsible party
Fulya Bakılan (Principal Investigator, Eskisehir City Hospital) — Principal investigator
First posted
Mar 28, 2023
Start date
Apr 16, 2021
Primary completion
Jul 25, 2021
Completion
Jul 31, 2021
Last update
Mar 30, 2023

Study contacts

Fulya Bakılan, Assoc. Prof.
principal investigator · Eskişehir Osmangazi University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion